HSF1 and breast cancer: Interestingly, research by Yallowtiz and colleagues [63] showed that lapatinib-resistant breast cancer cells have chronically activated HSF1 and heat shock proteins, but that these cells can be sensitised to treatment using HSF1 inhibitors.